Image For Activity Cover
Mastering Clozapine: Increasing Confidence and Improving Outcomes


This 12-week learning collaborative will serve as a virtual community for participants to gain knowledge of evidence-based principles for prescribing clozapine for patients with serious mental illness (SMI). Clozapine can be very rewarding to prescribe, since about half of patients with prior poor treatment response get substantially better with clozapine. This medication can result in major improvements in patients’ functioning and quality of life.  

Program Schedule  

The facilitated 12-week syllabus will be held from April 1 to June 30, 2023. No content will be released during the week of May 6, 2024.  

Please note you must complete all 13 modules in order to claim credit for this course. 

Module Opens 



Office Hours 

Mar 25 


Pre-work: Welcome and Introduction 


Apr 1 


Clozapine Overview: Efficacy and Mechanism of Action  


Apr 8 


Pharmacokinetics and Interpreting Clozapine levels 

Wed, 4/10 @ 3:00-3:30pm ET 

Apr 15 


Hematological Considerations and Side Effects  


Apr 22 


Metabolic Considerations and Side Effects  

Wed 4/24 @ 3:00-3:30pm ET 

Apr 29 


Cardiac Considerations and Side Effects  


May 13 


GI Considerations and Side Effects  

Wed, 5/15 @ 3:00-3:30 pm ET 

May 20 


Other Side Effects (Sialorrhea, Pneumonia, VTE, Enuresis) 


May 27 


Neurological Side Effects  

Wed, 5/29 @ 3:00-3:30 pm ET 

Jun 3 


Managing Partial Response and Treatment Resistance 


Jun 10 


Team-based approaches to clozapine (e.g., clozapine clinics) 

Wed, 6/12 @ 3:00-3:30pm ET 

Jun 17 


Measuring side effects 


Jun 24 


Presentation of SE monitoring protocol 

Wed, 6/26 @ 3:00-4:00pm ET (1 hour) 

Jun 30 


Program Schedule/Syllabus Ends 



FREE - $0 

Learning Objectives  

  • Identify patients who are appropriate candidates for clozapine 
  • Evaluate the balance between clozapine and efficacy for control of psychiatric symptoms with that of common side effects. 
  • Review major organ systems for how to assess and mitigate clozapine side effects 
  • Develop and implement a scale to monitor for side effects for patients taking clozapine. 

Target Audience  

Clinicians that are prescribing clozapine to individuals with SMI. [MD/DO, PMHNP, PMH-RN, PA] 

Instructional Level  

Introductory; Intermediate 

Estimated Time to Complete 

Estimated Duration: 15.0 hours  
Program Start Date: April 1, 2024 

Program End Date: June 30, 2024 

Credit Available Until: August 29, 2024 

How to Earn Credit 

Participants who wish to earn continuing medical education (CME) or a certificate of participation may do so by completing all sections of the course including the program evaluation. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians) or certificate of participation (other professions) showing the date of completion and hours earned. 

Continuing Education Credit 

In support of improving patient care, the American Psychiatric Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  


The APA designates this blended activity for a maximum of 15.0AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Faculty and Planner Disclosures 

The American Psychiatric Association adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Medical Education. Any individuals in a position to control the content of a CME activity — including faculty, planners, reviewers or others — are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.  


  • Robert O. Cotes, MD. Emory University School of Medicine. Disclosures – Consultant: Saladax Biomedical, HLS Therapeutics (unpaid); Research funding (to institution): Otsuka, Roche, Karuna, Alkermes.  Speaker: Clinical Care Options. 


  • John Torous, MD, Beth Israel Deaconess Medical Center. Dr. Torous has no relevant financial relationships to disclose. 
  • Teri Brister, PHD, LPC, National Alliance for Mental Illness. Dr. Brister has no relevant financial relationships to disclose. 
  • Donna Rolin, PhD, APRN, PMHCNS-BC, PMHNP-BC, University of Texas School of Nursing. Dr. Rolin has no relevant financial relationships to disclose. 
  • Robert O. Cotes, MD. Emory University School of Medicine. Disclosures – Consultant: Saladax Biomedical, HLS Therapeutics (unpaid); Research funding (to institution): Otsuka, Roche, Karuna, Alkermes.  Speaker: Clinical Care Options. 

Accessibility for Participants with Disabilities 

The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. If you have trouble accessing any of APA’s online resources, please contact us at 202-559-3900 for assistance.  

Availability: On-Demand
Access expires on 08/29/2024
Credit Offered:
15 CME Credits
15 COP Credits
Contains: 19 Courses
Funding for SMI Adviser was made possible by Grant No. SM080818 from SAMHSA of the U.S. Department of Health and Human Services (HHS). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, SAMHSA/HHS or the U.S. Government.
Powered By